Search
Aclaris Therapeutics Inc
ACRSAdd to Watchlist
5.560USD
+0.220+4.12%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
776.53MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.12%
5 Days
+13.24%
1 Month
+20.09%
6 Months
+93.06%
Year to Date
+84.72%
1 Year
+283.45%
Key Figures
5.360Open
5.580High
1.94MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.61%Turnover Ratio
5.340Prev. Close
5.325Low
7.01MTurnover
LossP/E Static
6.50P/B
0.00%Div Yield TTM
-35.11%ROA
5.15052wk High
1.02Volume Ratio
-132.06MNet Profit
120.50MShares
-0.5604EPS TTM
0.78Beta
-48.42%ROE
1.34352wk Low
4.78%Amplitude
10.42%Gross Margin
776.53MMarket Cap
3.97Reward/Risk
5.24%Risk Rate
TradingKey Stock Score of Aclaris Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Aclaris Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 80 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.15.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aclaris Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Aclaris Therapeutics Inc Highlights
StrengthsRisks
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.83M.
Undervalued
The company’s latest PE is -9.92, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 101.56M shares, increasing 0.01% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 22.21K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.27.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
9.150
Target Price
+82.27%
Upside Space
Aclaris Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aclaris Therapeutics Inc Info
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
Ticker SymbolACRS
CompanyAclaris Therapeutics Inc
CEOWalker (Neal S)
Websitehttps://www.aclaristx.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53002.700
+160.200 (+0.30%)
29618.200
+306.800 (+1.05%)
7512.800
+41.300 (+0.55%)
15011.000
+208.000 (+1.41%)
69801.000
+1653.000 (+2.43%)
6388.700
+35.900 (+0.56%)
68.863
+0.519 (+0.76%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4172.420
+50.510 (+1.23%)
FAQs
What is the current price of Aclaris Therapeutics Inc (ACRS)?
The current price of Aclaris Therapeutics Inc (ACRS) is 5.56.
What is the symbol of Aclaris Therapeutics Inc?
The ticker symbol of Aclaris Therapeutics Inc is ACRS.
What is the 52-week high of Aclaris Therapeutics Inc?
The 52-week high of Aclaris Therapeutics Inc is 5.15.
What is the 52-week low of Aclaris Therapeutics Inc?
The 52-week low of Aclaris Therapeutics Inc is 1.34.
What is the market capitalization of Aclaris Therapeutics Inc?
The market capitalization of Aclaris Therapeutics Inc is 669.98M.
Is Aclaris Therapeutics Inc (ACRS) currently rated as Buy, Hold, or Sell?
According to analysts, Aclaris Therapeutics Inc (ACRS) has an overall rating of Buy, with a price target of 9.15.
What is the Earnings Per Share (EPS TTM) of Aclaris Therapeutics Inc (ACRS)?
The Earnings Per Share (EPS TTM) of Aclaris Therapeutics Inc (ACRS) is -0.53.